These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 28277855)

  • 1. Using lower cost statins improves outcomes for normal cholesterol non-diabetic patients.
    Arbel R; Greenberg D
    Expert Rev Pharmacoecon Outcomes Res; 2017 Oct; 17(5):495-501. PubMed ID: 28277855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C; Ruff L; Balu S
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
    Cosin Sales J; Fuentes Jiménez FJ; Mantilla Morató T; Ruiz E; Becerra V; Aceituno S; Ferrario MG; Lizán L; Gracia A
    Clin Investig Arterioscler; 2015; 27(5):228-38. PubMed ID: 25640158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
    Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
    Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
    Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals.
    Mihaylova B; Briggs A; Armitage J; Parish S; Gray A; Collins R;
    Lancet; 2005 May 21-27; 365(9473):1779-85. PubMed ID: 15910950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin cost-effectiveness in the United States for people at different vascular risk levels.
    Heart Protection Study Collaborative Group
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):65-72. PubMed ID: 20031817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Nov; 34(41):3182-90. PubMed ID: 23886915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.